Publications
Detailed Information
Role of Postoperative Radiotherapy After Curative Resection and Adjuvant Chemotherapy for Patients With Pathological Stage N2 Non-Small-Cell Lung Cancer: A Propensity Score Matching Analysis
Cited 24 time in
Web of Science
Cited 28 time in Scopus
- Authors
- Issue Date
- 2014-09
- Publisher
- Cancer Information Group
- Citation
- Clinical Lung Cancer, Vol.15 No.5, pp.356-364
- Abstract
- This study evaluates the impact of postoperative radiotherapy in 219 patients with pN2 NSCLC after curative resection. After propensity score matching, PORT significantly increases LRC but not OS. Patients with multiple station mediastinal lymph node metastases or squamous cell carcinoma histology appear to benefit from PORT in terms of DFS. Risk factor based adjuvant treatment might be considered. Background: The objective of this study was to evaluate the role of postoperative radiotherapy (PORT) in the setting of adjuvant chemotherapy for pathological stage N2 (pN2) non-small-cell lung cancer (NSCLC). Materials and Methods: A retrospective review of 219 consecutive pN2 NSCLC patients who underwent curative surgery followed by adjuvant chemotherapy was performed. Forty-one patients additionally received PORT. Propensity scores for PORT receipt were individually calculated and used for matching to compare the outcome between patients who did (+) and did not (-) receive PORT. One hundred eleven patients in the PORT (-) group and 38 patients in PORT (+) group were matched. Clinical and pathologic characteristics were well-balanced. Results: The median follow-up duration was 48 months. In the matched patients, PORT resulted in a significantly lower crude locoregional relapse (43.2% vs. 23.7%; P = .032). Also, PORT was associated with improved locoregional control (LRC) rate (5-year LRC 63.7% vs. 48.6%; P = .036), but not distant metastasis-free survival, disease-free survival (DFS), and overall survival. An exploratory subgroup analysis suggested a potential DFS benefit of PORT in patients with multiple station mediastinal lymph node metastases (5-year DFS, 43.2% vs. 16.6%; P = .037) and squamous cell carcinoma histology (5-year DFS, 70.1% vs. 23.3%; P = .011). Conclusions: Even in the setting of adjuvant chemotherapy, PORT significantly increased LRC for patients with curatively resected pN2 NSCLC. Some subgroups appear to benefit from PORT in terms of DFS and LRC. Individualized strategies based on risk factors might be considered.
- ISSN
- 1525-7304
- Files in This Item:
- There are no files associated with this item.
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.